Background Significant positive bias of bilirubin in the Trinder salicylate method on automated analysers has been reported. Because the fluorescence polarization immunoassay (FPIA) for salicylate is also widely used in the clinical laboratory, we studied the potential interference of bilirubin in the salicylate FPIA.
Methods Salicylate serum pools (three different pools) were prepared from patients receiving salicylate. We also prepared a normal serum pool containing no salicylate and serum pools containing no salicylate but elevated bilirubin. Aliquots of one salicylate pool were supplemented with various concentrations of bilirubin (42. .5 mmol/L) and salicylate concentrations were measured by the salicylate FPIA (TDxFLx and AxSYM analysers). We also assayed these specimens with the Trinder salicylate method, using both Synchron LX and Hitachi 917 analysers for comparison with the results obtained by the FPIA method. In another experiment, aliquots of the two other salicylate pools were supplemented with various concentrations of bilirubin (42. .0 mmol/L) in order to further study the effect of very high bilirubin concentrations on the salicylate FPIA. We also added known amounts of salicylate to serum pools containing elevated bilirubin but no salicylate and measured salicylate using the FPIA in order to study the recovery of salicylate in the presence of elevated bilirubin concentrations.
Results
The FPIA showed minimal interference from bilirubin. We also observed good recovery of salicylate when specimens high in bilirubin but containing no salicylate were supplemented with known amounts of salicylate and the FPIA was used for the measurement of salicylate concentration. However, we observed falsely low salicylate concentrations with the Trinder method using the Synchron LX (primary wavelength 560 nm, secondary wavelength 700 nm) analyser and falsely increased salicylate concentrations using the same reagent but the Hitachi 917 (primary wavelength 546 nm, no secondary wavelength) analyser in the presence of elevated bilirubin levels compared with the FPIA results.
Conclusion
We conclude that the FPIA for salicylate is not affected by high bilirubin concentrations up to 427.5 mmol/L. Acetylsalicylic acid (aspirin) is one of the most commonly used medications, both in the pure form and in combination with other medications. Virtually the total dose of aspirin is hydrolysed by both liver and blood esterases to salicylic acid, an active component which accounts for all the pharmacological activities of the parent drug. Salicylate overdose is a common problem in the emergency room, and routine measurement of salicylate is performed in many clinical laboratories. Broughton 
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can be measured using a spectrophotometer at 540 nm. 1 In contrast, Savory and Souster reported that the interference of bilirubin in Trinder salicylate assay on Olympus AU 600 was negative; these authors used bichromatic measurement at 540 nm and 700 nm. 2 Berkovitch et al. reported falsely high serum salicylate concentrations using the same Trinder colorimetric method and an Hitachi 917 chemistry analyser; they observed an apparent salicylate concentration of 586.4 mmol/L using this method in a comatose child with elevated bilirubin in the absence of reported salicylate intake. 3 Thus interference of bilirubin in the Trinder salicylate assay is problematic.
The £uorescence polarization immunoassay (FPIA) for salicylate is available from Abbott Laboratories. This assay uses a polyclonal antibody and, according to the package insert, the assay is not a¡ected by bilirubin up to a concentration of 256.5 mmol/L. This salicylate assay can be run using an AxSYM analyser, or a smaller clinical laboratory can use a bench-top TDxFLx analyser. Because from time to time we encounter bilirubin concentrations as high as 684.0 mmol/ L in our laboratory, we studied the e¡ect of such high bilirubin concentrations on the salicylate FPIA. For comparison purposes, we also studied the Trinder salicylate assay using the Synchron LX20 and Hitachi 917 analysers.
Materials and methods
Salicylate and bilirubin were purchased from Sigma Chemical Company (St Louis MO, USA). The FPIA for salicylate was purchased from Abbott Laboratories (Abbott Park IL, USA) and the assay was performed using a TDxFLx analyser and an AxSYM analyser; both analysers are marketed by Abbott Laboratories. The Trinder salicylate assay reagent system and standards were purchased from Sigma Diagnostics. The assays were run on a Synchron LX 20 analyser (Beckman Coulter, Brea CA, USA) and an Hitachi 917 analyser (Roche Diagnostics, Indianapolis IN, USA).
The concentration of bilirubin in serum was measured using an Hitachi 917 analyser; the reagent system was also available from Roche Diagnostics. A standard solution of salicylate (10 mg/mL) was prepared in distilled water. A standard solution of bilirubin was prepared in 0.1 M potassium hydroxide.
We prepared three salicylate serum pools from patients receiving salicylate. We prepared one normal pool containing no salicylate. Four serum pools from specimens containing elevated bilirubin were also prepared; these pools contained no salicylate. We routinely receive such specimens in our clinical laboratory for various tests. We used leftover specimens for our study after performing and reporting all tests to the ordering clinician. The specimens would otherwise be discarded.
We added various amounts of bilirubin to aliquots of normal pool 1 (no salicylate). Aliquots of salicylate pool 1 were also supplemented with various concentrations of bilirubin. The salicylate concentrations in all aliquots were measured by the FPIA on the TDxFLx and AxSYM analysers.We also used Trinder reagent to measure salicylate concentrations on the Synchron LX and Hitachi 917 analysers in order to compare the results with those obtained by the FPIA.We added only microlitre amounts of bilirubin standard solution to millilitre aliquots of normal pool and salicylate pool to keep the dilution at a minimum level.
The salicylate assay using Trinder reagent on the Synchron LX 20 analyser uses a primary wavelength at 560 nm and a secondary wavelength at 700 nm as recommended by the manufacturer of the salicylate colorimetric assay (Sigma Diagnostics). However, the same manufacturer recommended a primary wavelength of 546 nm for the salicylate assay on the Hitachi 917 analyser.
In order to con¢rm that bilirubin does not a¡ect the salicylate FPIA, aliquots of salicylate pools 2 and 3 were supplemented with various concentrations of bilirubin and salicylate concentrations in the presence of bilirubin were compared with control values (no bilirubin added). Salicylate concentrations were measured using both TDxFLx and AxSYM analysers. The salicylate FPIA is linear up to a salicylate concentration of 5792.0 mmol/L and the sensitivity of the assay is 36.2 mmol/L.
We also added known amounts of salicylate to aliquots of serum pools containing no salicylate but elevated levels of bilirubin (bilirubin pool 1-4). Again salicylate concentrations were measured by both instruments and compared with the target values.
Statistical analysis was performed using the t-test, two-tailed. We considered a di¡erence to be statistically signi¢cant only at a con¢dence level of 95% or higher (P50.05).
Results
When aliquots of normal pool 1 were supplemented with bilirubin, we observed no apparent salicylate concentration using the salicylate FPIA. We also observed no apparent salicylate concentration using the Trinder reagent and the Synchron LX 20 analyser using a primary wavelength 560 nm and a secondary wavelength of 700 nm. Interestingly, we observed a signi¢cant apparent salicylate concentration when the same reagent was used on the Hitachi 917 analyser for salicylate measurement when only the primary wavelength at 546 nm was used for the colorimetric determination. In the presence of 466.8 mmol/L of bilirubin, in one aliquot of the drug-free serum, the observed apparent salicylate concentration was 579.2 mmol/L (see Table 1 ).
We observed no interference from bilirubin in the salicylate FPIA using both the TDxFLx and AxSYM analysers when aliquots of serum pool containing salicylate (salicylate pool 1) were further supplemented with bilirubin, indicating that the FPIA is free from interference up to a bilirubin concentration of 466.8 mmol/L. For example, the concentration of salicylate in salicylate pool 1 was 974.5 mmol/L as observed with the FPIA assay and TDxFLx analyser. In the presence of 461.7 mmol/L of bilirubin, the observed salicylate concentration was 1017.2 mmol/ L, a value not statistically di¡erent from the control value of 974.5 mmol/L (see Table 1 ).
However, we observed falsely low salicylate concentrations in the presence of elevated concentrations of bilirubin when the Synchron LX 20 analyser was used for salicylate measurement. For example, the apparent salicylate concentration signi¢cantly dropped from a control value of 1114.9 mmol/ L (bilirubin 5.1 mmol/L) to 832.6 mmol/L in the presence of 83.7 mmol/L bilirubin. In the presence of 184.6 mmol/L bilirubin, the salicylate level was below the detection limit of the instrument. In contrast, we observed falsely increased salicylate concentrations when the Trinder reagent was used in the Hitachi 917 analyser. In this case, the control salicylate value was 1049.8 mmol/L (bilirubin 5.1 mmol/L). The apparent salicylate concentration increased to 2027.2 mmol/L in the presence of 461.7 mmol/L bilirubin (see Table 1 ).
The package insert for the salicylate FPIA (Abbott Laboratories) claims less than 10% error in salicylate measurement in the presence of 256.5 mmol/L bili- Added Assayed TDxFLx AxSYM 1.7 mmol/L). However, with 608.7 mmol/ L and 695.9 mmol/L bilirubin, the observed salicylate concentrations were 1799.1 and 1833.1 mmol/L, respectively. These values were statistically di¡erent from the control value, but 8.6% and 10.6% positive bias in the salicylate measurement should not have a clinically signi¢cant e¡ect on the interpretation of the results. We observed similar results when aliquots of salicylate pool 3 were supplemented with various concentrations of bilirubin (see Table 2 ). We also observed good correlation between target and observed salicylate concentrations when serum pools containing elevated bilirubin (bilirubin pools 1-4) were supplemented with known amounts of salicylate (seeTable 3). For example, when a serum pool containing 111.2 mmol/L bilirubin but no salicylate was supplemented with 2534.0 mmol/L salicylate, the observed salicylate concentration using the AxSYM analyser was 2514.4 mmol/L. The good recoveries observed when serum pools containing elevated levels of bilirubin were supplemented with known amounts of salicylate further demonstrate that the salicylate FPIA is not signi¢cantly a¡ected by bilirubin.
Discussion
A popular method for the determination of salicylate in serum is based on the method of Trinder, which is the classical colorimetric method. 3, 5, 6 In a comparative study of specimens from 115 patients, results obtained by the Trinder method agreed well with a reference high-performance liquid chromatography (HPLC) procedure. 7 However, the interference of bilirubin in the Trinder salicylate method can cause signi¢cant problems in the clinical interpretation of the results. The package insert for theTrinder salicylate assay does not speci¢cally address bilirubin interference; only one statement was found in the package insert that certain drugs and other substances are known to in£uence circulating salicylate concentrations (Sigma Diagnostics). However, Broughton et al. concluded in their study that this interference can give rise to false information when assessing patients who have been admitted to hospital with a suspected overdose. It also can cause unnecessary investigations in patients with jaundice whose salicylate concentration was measured. This interference is caused by the reaction of bilirubin with ferric ion, and sample blanking does not overcome this problem. Broughton et al. suggested pre-incubation of specimens with bilirubin oxidase to overcome this problem. 1 Barlow et al. also reported similar interference in salicylate measurement using the RA-1000 analyser. This analyser uses a modi¢ed micro-scale Trinder method in which the absorbance of salicylate -ferric ion complex is measured at 550 nm. 4 Berkovitch et al. also showed signi¢cant positive interference from bilirubin in the Trinder salicylate assay on the Hitachi 917 analyser. In the presence of 256.5 mmol/L bilirubin, the apparent salicylate concentration was 644.4 mmol/L in a neonate. However, no salicylate was detected using the salicylate FPIA on the AxSYM analyser. 3 We observed positive interference by bilirubin in the Trinder method when a single wavelength was used for the measurement (Hitachi 917 analyser). This observation is in agreement with Berkovitch et al. 3 However, when we used both a primary and a secondary wavelength, as recommended by the manufacturer (Synchron LX 20 analyser), bilirubin caused signi¢cant negative interference. Therefore, bilirubin can cause both positive and negative interference in this method depending on whether monochromatic or bichromatic measurement is used.
Our results clearly indicate that bilirubin does not interfere signi¢cantly in salicylate measurement by FPIA. Berkovitch showed that bilirubin concentrations up to 15 mg/dL in neonates did not cause any interference in the salicylate measurement by the AxSYM analyser. 3 Karnes and Beightol earlier evaluated the analytical performance of the salicylate FPIA by comparing it with an HPLC reference method, but they did not study the potential interference of bilirubin. 8 Our results show that the FPIA salicylate method is not a¡ected by bilirubin, even at a concentration of 427.5 mmol/L.We observed positive bias only at bilirubin concentrations of 598.5 and 684.0 mmol/L. However, even at 684.0 mmol/L, the positive bias was only 10.6-16%; this small bias should not cause any signi¢cant problem in interpreting salicylate concentrations. We conclude that the FPIA for salicylate is virtually free from interference from bilirubin and that the assay can be used in clinical laboratories for accurate determination of serum salicylate concentrations.
